Oberg, D., Yanover, E., Adam, V., Sweeney, K., Costas, C., Lemoine, N. R., & Halldén, G. (2010). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clinical cancer research, 16(2), 541. https://doi.org/10.1158/1078-0432.CCR-09-1960
Chicago-Zitierstil (17. Ausg.)Oberg, Daniel, Eva Yanover, Virginie Adam, Katrina Sweeney, Celina Costas, Nick R. Lemoine, und Gunnel Halldén. "Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers." Clinical Cancer Research 16, no. 2 (2010): 541. https://doi.org/10.1158/1078-0432.CCR-09-1960.
MLA-Zitierstil (9. Ausg.)Oberg, Daniel, et al. "Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers." Clinical Cancer Research, vol. 16, no. 2, 2010, p. 541, https://doi.org/10.1158/1078-0432.CCR-09-1960.